These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effects of entecavir and Shenxian Yiganling combination therapy on patients with HBeAg-positive chronic hepatitis B for 48 weeks].
    Author: Zhang T, Wang Y, Sun KW.
    Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):180-2. PubMed ID: 22574588.
    Abstract:
    OBJECTIVE: To evaluate of the efficacy and safety of entecavir (ETV) combined with Shenxian Yiganling (SY) versus ETV therapy on patients with HBeAg-positive chronic hepatitis B (CHB) for 48 weeks. METHODS: One hundred and sixty-four CHB patients were assigned to two groups with the cohort study: the ETV combined with SY treatment group and the ETV control group. The alanine aminotransferase (ALT), the undetectable HBV DNA level, and HBeAg negative conversion rate, and HBeAg serological negative conversion rate were observed before and after treatment. RESULTS: At week 48, there was no significant difference in the normalization of ALT levels (70.00% vs 67.61%, P > 0.05) and undetectable HBV DNA levels (72.50% vs 73.24%, P > 0.05) between the two groups. There was significant difference in the HBeAg negative conversion rate (39.44% vs 23.75%) and HBeAg serological negative conversion rate (32.39% vs 15.00%) (both P < 0.05). CONCLUSION: ETV combined with SY promoted the HBeAg serological negative conversion rate possibly through the recovery of the immune functions.
    [Abstract] [Full Text] [Related] [New Search]